Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
0.8900
-0.0299 (-3.25%)
Jul 16, 2026, 4:00 PM EDT - Market closed
Actinium Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2025
-
The conference highlighted a robust pipeline in targeted radiotherapy, with lead programs advancing in AML, solid tumors, and cell/gene therapy. Promising clinical data, large market opportunities, and a strong financial position support continued growth and partnership opportunities.
-
Multiple revitalized clinical programs, including Actimab-A and Iomab-ACT, are advancing with new trials in AML and solid tumors, supported by strong financials and enhanced R&D. A novel prostate cancer therapy, ATNM-400, showed promising preclinical results.